Progressive Supranuclear Palsy, Corticobasal Degeneration, and Multiple System Atrophy

Area of Science:

• Neurodegenerative diseases
• Movement disorders
• Neurology

Background:

• Idiopathic Parkinson disease (IPD) is often misdiagnosed in patients presenting with parkinsonian features unresponsive to levodopa.
• Progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and corticobasal degeneration (CBD) are key differential diagnoses.
• Accurate diagnosis is essential for patient management, despite limited therapeutic options for these conditions.

Observation:

• Clinical presentation and pathological findings in PSP, MSA, and CBD are not always concordant.
• Symptoms may not reliably predict underlying pathology or clinical syndrome.
• Emerging research focuses on targeting misfolded tau (PSP, CBD) and alpha-synuclein (MSA).

Findings:

• Characteristic signs and symptoms of PSP, MSA, and CBD are vital for differentiating them from IPD.
• Early diagnostic signs may be subtle and not present at disease onset.
• Understanding these distinctions improves diagnostic accuracy in atypical parkinsonism.

Implications:

• Timely diagnosis of PSP, MSA, and CBD is critical for appropriate patient care and management strategies.
• Despite challenges in predicting pathology from symptoms, therapeutic strategies targeting specific proteinopathies are under investigation.
• Enhanced clinical recognition of these disorders is essential for advancing research and treatment.